Patient data collective and research matching AI
Hyper-Care
Hyper-Care describes patient-controlled record use, sponsor choice, study matching, and shared commercial value. These remain design claims. Key custody, revocation, compensation terms, and access without research participation are not independently established.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Mixed 5 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Patient data collective and AI advocate design, including research matching and shared commercial value. Operational implementation remains unverified.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | AI that is designed to assist you and keep your health data and interactions confidentialSource Marketing page labels a 'Safe AI Advocate'. No product screen or consent step was seen. |
| 2. Operator and model maker named | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Hyper-Care is named as a Public Benefit Corporation (Values page), but no AI model or model maker is named in any page read. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | Register an account, and connect your health dataSource FAQ answer to 'How do I join'. The advocacy-group path ('activates patient community from directory') may differ, and no terms or privacy policy were found. |
| 4. Patient sets the task | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Marketing says 'keeping every decision under your control', but nothing documents that the patient sets what the AI advocate does. The platform is also built around study matching and research revenue. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | Register an account, and connect your health dataSource Self-started tool rule: Q3 is yes and no care depends on it. Source is the Q3 source. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | from spotting trends to explaining your results in plain languageSource Marketing description of the AI advocate output. Not verified in a product. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. No documented route to correct or contest AI output. |
| 8. Patient can get a copy | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Pages say 'You hold the encryption keys' and data sits in personal data pods, but no export or copy route is documented. |
| 9. Patient can delete | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. No deletion route documented in the pages read. |
| 10. Training or sale does not override patient choice | Yes | documented Not independently replicated | No data leaves your secure pod without your explicit, "opt-in" permissionSource The FAQ also says data is not sold 'without your consent'. Model training is not addressed. Marketing only, no binding terms found. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Solid pods are named, but no way to run the tool yourself or move the function elsewhere is documented. |
| 12. No advertising or data business | No | documented Not independently replicated | Life Sciences Pay Us: Companies pay for access to anonymized, high-quality datasets to speed up drug developmentSource Documented data business: the Trust page says they 'monetize aggregated insights' and share revenue with patients. Payment to patients and consent do not change the Q12 rule. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Potentially agency-expanding, with commercialization and disclosure caveats
Legacy editorial placement, pre-method: 78
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 78
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 78. Not comparable with v1.3 positions.
Potentially agency-expanding, with commercialization and disclosure caveats
Hyper-Care describes patient-controlled record use, sponsor choice, study matching, and shared commercial value. These remain design claims. Key custody, revocation, compensation terms, and access without research participation are not independently established.
Patient agency
How this tool changes agency
Record explanation and study discovery could support informed action. No reviewed page establishes correction or appeal of an AI inference or an eligibility exclusion.
Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified
Patient agency assessment
Who sets and changes the goal?
The described ability to select sponsors and control release is agency-relevant. Payment for contributing data does not itself establish governance rights or permission to refuse research while retaining care tools.
What can the patient understand, question, or do?
Record explanation and study discovery could support informed action. No reviewed page establishes correction or appeal of an AI inference or an eligibility exclusion.
Can the patient evaluate the conditions of use?
Transparency promises are specific but remain promises. Encryption in transit and at rest does not alone establish that only the patient can decrypt data.
Text findings
Conditions of use
Published controls and their limits
Transparency promises are specific but remain promises. Encryption in transit and at rest does not alone establish that only the patient can decrypt data.
What remains unknown?
Not tested or not established
Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Low to moderate for design claims, low for operational guarantees (AI-assisted draft)